Pharmafile Logo
Pharmafocus logo
Advanced Search

tecentriq

Showing 15 posts of 48 posts found.

roche__tree

Roche voluntarily withdraws Tecentriq’s US bladder cancer indication

March 8, 2021
Sales and Marketing Cancer, Roche, bladder cancer, tecentriq

Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …

News
tecentriq

Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer

July 13, 2020
Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq

Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …

News

Roche’s Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3

June 19, 2020
Medical Communications, Research and Development Cancer, Genentech, Roche, breast cancer, tecentriq

 

News

NICE reverses previous stance to recommend Roche’s Tecentriq in extensive-stage small-cell lung cancer

May 27, 2020
Research and Development, Sales and Marketing NICE, Roche, lung cancer, tecentriq

NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new …

News

Roche’s Tecentriq falls short as an adjuvant monotherapy in muscle-invasive urothelial cancer

January 24, 2020
Medical Communications, Sales and Marketing Cancer, Roche, pharma, tecentriq, trial failure

Roche has released an update on the development of its immunology Tecentriq (atezolizumab), making it known that the drug failed …

News
roche

Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

December 16, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …

News
tecentriq

Roche’s Tecentriq combo scores FDA approval in non-small cell lung cancer

December 4, 2019
Research and Development, Sales and Marketing FDA, NSCLC, Roche, pharma, tecentriq

Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane …

News
roche__tree

Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma

November 25, 2019
Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …

News
rocheshanghai

Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma

October 21, 2019
Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …

News
rocherooflr

NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

October 3, 2019
Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …

News
roche__tree

Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer

October 1, 2019
Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq

Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …

News

Roche celebrates European approval of Tecentriq combo in first-line lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq

Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …

News
roche__tree

Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer

August 30, 2019
Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq

Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …

News

Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial

August 5, 2019
Sales and Marketing Cancer, Roche, bladder cancer, immunotherapy, oncology, tecentriq

Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of …

News
images

Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer

July 29, 2019
Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq

Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024